Article
Oncology
A. S. Fung, D. M. Graham, E. X. Chen, T. L. Stockley, T. Zhang, L. W. Le, H. Albaba, K. M. Pisters, P. A. Bradbury, M. Trinkaus, M. Chan, S. Arif, U. Zurawska, J. Rothenstein, D. Zawisza, S. Effendi, S. Gill, M. Sawczak, J. H. Law, N. B. Leighl
Summary: The combination of binimetinib with carboplatin and pemetrexed appears to have manageable toxicity and evidence of activity in advanced non-squamous NSCLC.
Article
Oncology
Ryan D. Gentzler, Nisha A. Mohindra, Shadia Jalal, Karen L. Reckamp, Richard D. Hall, Nasser H. Hanna, Young Kwang Chae, Marianna Koczywas, Irene B. Helenowski, Jyoti D. Patel
Summary: Combination chemotherapy and immunotherapy have improved survival for advanced NSCLC patients. The study showed that when using nab-paclitaxel in combination with pembrolizumab, overall survival was improved regardless of PD-L1 status compared to chemotherapy alone.
Article
Oncology
Ajay Yadav, Prabhat Singh Malik, Sachin Khurana, Deepali Jain, Sreenivas Vishnubhatla, Mukesh Yadav, Sushmita Pathy, Anant Mohan, Lalit Kumar
Summary: The study comparing pemetrexed-carboplatin with (weekly) paclitaxel-carboplatin in treatment-naive advanced non-squamous NSCLC patients without driver mutations showed no significant difference in progression-free survival and overall survival between the two treatment arms.
Article
Oncology
David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore III, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar
Summary: This study aimed to investigate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel for advanced or recurrent non-small-cell lung cancer. The results showed that the addition of bevacizumab improved overall response and time to progression, but bleeding was the most prominent adverse event. Patients with nonsquamous cell histology appeared to have better treatment outcomes and acceptable safety risks.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Satoru Miura, Yasuhiro Koh, Koichi Azuma, Hiroshige Yoshioka, Kenichi Koyama, Shunsuke Teraoka, Hidenobu Ishii, Kayoko Kibata, Yuichi Ozawa, Takaaki Tokito, Jun Oyanagi, Toshio Shimokawa, Takayasu Kurata, Nobuyuki Yamamoto, Hiroshi Tanaka
Summary: The aim of this study was to determine the safety and efficacy of combination treatment with osimertinib and afatinib for patients with acquired resistance to osimertinib. The maximum tolerated dose of afatinib when combined with osimertinib was determined as 30 mg, and the most frequent adverse events were diarrhea, anemia, and rash. The synergistic effect of afatinib with osimertinib may be limited in osimertinib-resistant patients.
Article
Medicine, General & Internal
Ibrahim Azar, Omid Yazdanpanah, Hyejeong Jang, Adam Austin, Seongho Kim, Jie Chi, Samer Alkassis, Biplab K. Saha, Amit Chopra, Kristoffer Neu, Syed Mehdi, Hirva Mamdani
Summary: There is no significant difference in survival outcomes between cisplatin and carboplatin for the treatment of both limited-stage and extensive-stage small cell lung cancer (SCLC). The favorable toxicity profile of carboplatin and comparable overall survival support its use in clinical practice for both types of SCLC and allow for combination with novel treatment strategies in clinical trials.
Article
Oncology
David E. Kozono, Thomas E. Stinchcombe, Joseph K. Salama, Jeffrey Bogart, W. Jeffrey Petty, Michael J. Guarino, Lyudmila Bazhenova, James M. Larner, Jared Weiss, Thomas A. DiPetrillo, Steven J. Feigenberg, Xin Chen, Zhaowen Sun, Silpa Nuthalapati, Lindsey Rosenwinkel, Eric F. Johnson, Bruce A. Bach, Yan Luo, Everett E. Vokes
Summary: This study evaluated the effects of veliparib in combination with chemoradiotherapy on patients with unresectable stage III NSCLC, demonstrating acceptable safety profile and antitumor activity with a median progression-free survival of 19.6 months.
Article
Oncology
Mariona Riudavets, Marie Naigeon, Matthieu Texier, Miriam Dorta, Fabrice Barlesi, Julien Mazieres, Andrea Varga, Lydie Cassard, Lisa Boselli, Jonathan Grivel, Maud NgoCamus, Ludovic Lacroix, Laura Mezquita, Benjamin Besse, Nathalie Chaput, David Planchard
Summary: This study evaluated the safety and efficacy of the combination of tremelimumab and gefitinib in patients with EGFR-mutant NSCLC. The results showed limited efficacy with this combination, with stable disease being the best overall response in most patients. Gastrointestinal toxicity was the main adverse reaction.
Article
Oncology
Hong Jian, Kai Wang, Ying Cheng, Lieming Ding, Yang Wang, Zhe Shi, Ling Zhang, Yaolin Wang, Shun Lu
Summary: This study evaluated the safety, tolerability, anti-tumor activity, and pharmacokinetics of D-0316 in patients with advanced NSCLC with EGFR T790M mutation. The results showed that D-0316 had good tolerability within the dose range of 25 to 150 mg, and the recommended phase II dose was 100 mg. In the 50 and 100 mg dose groups, the overall response rates were 33.3% and 45.5%, the disease control rates were 86.7% and 93.9%, and the median progression-free survival was 8.3 and 9.6 months, respectively.
Review
Oncology
Jamie E. Chaft, Andreas Rimner, Walter Weder, Christopher G. Azzoli, Mark G. Kris, Tina Cascone
Summary: The treatment goal for early-stage lung cancer patients is cure, with surgical resection or radiotherapy as definitive local treatments along with adjuvant therapy to improve the likelihood of cure. New therapies lag behind due to inefficient trial designs and lengthy follow-ups, despite efforts to study surrogate endpoints to shorten trial durations.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Surgery
Brendan T. Heiden, Daniel B. Eaton, Su-Hsin Chang, Yan Yan, Martin W. Schoen, Mayank R. Patel, Daniel Kreisel, Ruben G. Nava, Bryan F. Meyers, Benjamin D. Kozower, Varun Puri
Summary: The aim of this study was to compare quality of care and outcomes between Veteran and non-Veteran patients undergoing surgery for clinical stage I non-small cell lung cancer (NSCLC). The study found that Veterans receive high quality care through the VHA for lung cancer and have similar outcomes compared to the general population.
Article
Oncology
Yasuhiro Tsutani, Yoshihisa Shimada, Hiroyuki Ito, Yoshihiro Miyata, Norihiko Ikeda, Haruhiko Nakayama, Morihito Okada
Summary: In clinical stage I NSCLC, patients with a solid component size of >2 cm or pure solid type on HRCT were found to be at a high risk of recurrence. Dividing patients into high-risk and low-risk groups based on these factors showed a significant difference in recurrence-free survival.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Brendan T. Heiden, Daniel B. Eaton, Kathryn E. Engelhardt, Su-Hsin Chang, Yan Yan, Mayank R. Patel, Daniel Kreisel, Ruben G. Nava, Bryan F. Meyers, Benjamin D. Kozower, Varun Puri
Summary: This study found that surgical procedures delayed more than 12 weeks were associated with increased risk of recurrence and worse survival in patients with clinical stage I NSCLC, suggesting that timely treatment is crucial for better outcomes.
Article
Oncology
Akihiko Miyanaga, Hajime Asahina, Satoshi Watanabe, Takehito Shukuya, Yukari Tsubata, Yukio Hosomi, Shunichi Sugawara, Makoto Maemondo, Tetsuya Okano, Satoshi Morita, Kotone Matsuyama, Kunihiko Kobayashi, Masahiro Seike
Summary: This study aims to evaluate the safety and efficacy of necitumumab plus pembrolizumab, nanoparticle albumin-bound paclitaxel, and carboplatin therapy in previously untreated squamous cell lung cancer (SqCLC) patients. Phase I evaluates the tolerability and recommended dose of the combination therapy, while phase II assesses the overall response rate and secondary endpoints including disease control rate, progression-free survival, overall survival, and safety. It is the first study to investigate the efficacy and safety of necitumumab plus pembrolizumab combined with platinum-based chemotherapy in previously untreated SqCLC patients.
CLINICAL LUNG CANCER
(2023)
Article
Oncology
Corey J. Langer, Ajeet Gajra, Cesare Gridelli, Kartik Konduri, Daniel Morgensztern, David Spigel, Denis Talbot, Michael Thomas, Jared Weiss, Richard Pilot, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Mark Socinski
Summary: Despite the underrepresentation of certain patient populations in clinical trials for advanced NSCLC, a pooled analysis of elderly patients and those with renal impairment, diabetes, or poor performance status showed varying but promising outcomes, supporting the use of nab-paclitaxel-based regimens in these historically understudied and vulnerable populations.
FRONTIERS IN ONCOLOGY
(2021)